Brachytherapy is one of the most common radiation treatments for uterine (endometrial) cancer, used either after surgery to reduce the chance of the cancer coming back or, in patients who cannot have surgery, as a primary treatment to control the disease. The most frequent form involves placing a small applicator into the vagina to deliver radiation directly to the tissues most at risk of recurrence. For many patients with early-stage endometrial cancer, vaginal cuff brachytherapy after hysterectomy has replaced whole-pelvis external beam radiation as the standard of care, largely because it works just as well at preventing vaginal recurrence while causing far fewer side effects.
How Brachytherapy Fits Into Uterine Cancer Treatment
The role brachytherapy plays depends on the stage of the cancer and whether the patient has had surgery. The most common scenario is adjuvant vaginal cuff brachytherapy (VCB), given after a hysterectomy to patients whose tumors have features suggesting a moderate risk of the cancer recurring at the top of the vagina. In this setting, brachytherapy alone has become the preferred adjuvant treatment for many early-stage patients, replacing pelvic external beam radiotherapy. It provides equivalent control of vaginal recurrence with lower toxicity and minimal effect on quality of life.1PubMed Central. Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients – in view of the recent evidence
For patients who are medically inoperable, perhaps because of severe heart disease, obesity, or other conditions that make surgery too risky, brachytherapy takes on a larger role. These patients typically receive a combination of external beam radiation and high-dose-rate (HDR) brachytherapy delivered through applicators placed inside the uterus. In one study of medically inoperable patients, about 89% received the combination approach, while a smaller group was treated with brachytherapy alone.2PubMed Central. Definitive Radiation Therapy for Medically Inoperable Endometrial Carcinoma Long-term data on this approach are encouraging: a prospective study following inoperable patients for up to a decade found disease-specific survival rates above 85% for stage I disease and above 70% for stage II, with only mild late radiation side effects in about 14% of patients.3Journal of Radiation Research. Long-term Results of High-dose-rate Brachytherapy and External-beam Radiotherapy in the Primary Treatment of Endometrial Cancer
The Evidence That Changed Practice
The shift toward vaginal brachytherapy and away from whole-pelvis external beam radiation for many endometrial cancer patients rests largely on one landmark trial: PORTEC-2. This randomized trial compared the two approaches in patients with high-intermediate risk endometrial cancer and found virtually identical rates of vaginal recurrence at five years, roughly 1.8% with brachytherapy versus 1.6% with external beam radiation. Overall survival was also similar. The decisive difference was in side effects: only about 13% of brachytherapy patients had acute gastrointestinal symptoms compared with about 54% of those receiving external beam radiation.4PubMed. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
Ten-year follow-up confirmed the durability of those findings. Vaginal recurrence remained low in both groups, around 3.4% for brachytherapy and 2.4% for external beam. Pelvic recurrence outside the vagina was somewhat more common in the brachytherapy group (about 6% versus 1%), but most of those cases occurred alongside distant spread, meaning the cancer had already traveled beyond what either local treatment could reach. Overall survival at ten years was nearly identical at about 70% in both groups.5British Journal of Cancer. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy Comprehensive reviews of adjuvant vaginal brachytherapy studies report very low vaginal recurrence rates of 0 to 3%, reinforcing the conclusion that this approach works well for the right patients.6PubMed Central. Adjuvant Vaginal Brachytherapy for Early Stage Endometrial Cancer: A Comprehensive Review
When a Brachytherapy Boost Makes Sense
For patients whose tumors have higher-risk features, such as cancer invading the cervical stroma or certain stage III disease, the question shifts from “brachytherapy or external beam?” to “should brachytherapy be added on top of external beam radiation?” The evidence here is less clear-cut than for early-stage disease. Some data suggest that patients with cervical stromal involvement or select stage III cancers may get better local control and even survival benefits from adding a vaginal cuff boost after external beam treatment.7PubMed. The role for vaginal cuff brachytherapy boost after external beam radiation therapy in endometrial cancer Other factors, including tumor grade, how deeply the cancer invaded, and whether surgical margins were close, also weigh into that decision.
For patients with straightforward stage I or II disease who are already getting full pelvic radiation, though, older data found no added benefit from tacking on a vaginal cuff boost for pelvic control or disease-free survival.8PubMed. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer? The takeaway for patients: whether you need brachytherapy alone, external beam alone, or both together depends heavily on the specifics of your tumor and surgical findings.
What the Procedure Looks Like
If you have been told you need vaginal cuff brachytherapy after a hysterectomy, the procedure is typically an outpatient visit lasting under an hour. A cylindrical applicator is placed into the vagina, and the radiation source, usually iridium-192, is guided through it by a computer-controlled system. High-dose-rate delivery has largely replaced the older low-dose-rate method, which required long hospital stays with the source left in place for hours or days.9PubMed Central. Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer With HDR, each treatment session takes only minutes of actual radiation delivery, though setup and imaging add time.
A standard course involves somewhere between two and five treatment sessions, depending on the dose per session. A recent randomized trial tested a short-course schedule of just two sessions against standard regimens of three to five sessions and found the same vaginal control rate of 96% in both groups, with similar quality-of-life outcomes.10JCO Oncology Advances. Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared with Standard of Care (SAVE): A Randomized Clinical Trial Fewer trips to the treatment center is a real advantage for patients who live far from a radiation facility or who find the procedure uncomfortable.
Applicator Design and Why It Matters
The cylinder placed into the vagina may be a simple single-channel device or a multichannel applicator with several pathways for the radiation source. The multichannel design lets radiation oncologists shape the dose more precisely, potentially sparing the rectum and bladder. Dosimetric comparisons show that multichannel applicators reduce rectal dose by roughly 6 to 7% and bladder dose by about 11 to 12% compared with single-channel devices, without sacrificing coverage of the target tissue.11International Journal of Radiation Oncology, Biology, Physics. Dosimetric Comparison of Multi-Channel Versus Single-Channel Vaginal Cylinder Applicators in High Dose-Rate Vaginal Brachytherapy for Endometrial Cancer Another study confirmed a meaningful reduction in rectal dose with multichannel use.12PubMed Central. Single versus multichannel applicator in high-dose-rate vaginal brachytherapy optimized by inverse treatment planning
For inoperable patients whose uterus is still intact, the situation is more complex. Tandem-based applicators are threaded through the cervix into the uterine cavity. The shape of the uterus matters: in one study comparing single, dual, and triple tandem applicators, which configuration worked best depended on whether the uterus was elongated, round, or close to the bladder.13PubMed. The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer In challenging anatomies, creative approaches have emerged, such as combining a Y-shaped applicator with a standard tandem to improve tumor coverage while keeping doses to surrounding organs low.14PubMed Central. Combination of Rotte Y Applicator and Standard Tandem for Medically Inoperable Endometrial Cancer When standard intracavitary devices cannot adequately cover large or irregularly shaped tumors, interstitial brachytherapy, which places needles directly through the tissue, can dramatically improve the dose reaching the tumor.15International Journal of Gynecological Cancer. Computed Tomography-Guided Interstitial Brachytherapy for Locally Advanced Cervical Cancer: Introduction of the Technique and a Comparison of Dosimetry With Conventional Intracavitary Brachytherapy
Side Effects You Should Know About
Compared with external beam radiation, vaginal cuff brachytherapy is well tolerated. A 2025 study of patients who received HDR vaginal cuff brachytherapy found that only about 6% experienced any acute gastrointestinal symptoms and about 7% had acute urinary symptoms. Chronic toxicity was slightly more common, at roughly 15% for both gastrointestinal and genitourinary issues, but severe (grade 3) events were rare, with only two cases in the entire cohort.16PubMed. Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer
Vaginal stenosis, a narrowing and shortening of the vagina, is probably the side effect patients worry about most. One year after radiotherapy, a study found that vaginal diameter had decreased by an average of about 2.7 millimeters, and roughly two-thirds of patients had some degree of clinical vaginal stenosis.17PubMed. The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer Vaginal dilator use is routinely recommended after treatment to help maintain vaginal length and width, though adherence varies widely. Emerging treatments such as hyaluronic acid and laser therapy are being explored for radiation-induced stenosis, but data remain preliminary.18PubMed Central. Pelvic Radiation Therapy Induced Vaginal Stenosis: A Review of Current Modalities and Recent Treatment Advances
Does Brachytherapy Affect Quality of Life and Sexual Function?
This is a question many patients ask but may feel awkward bringing up. The reassuring answer from the available data is that vaginal cuff brachytherapy after surgery does not appear to measurably worsen overall quality of life or sexual function compared with surgery alone. A study that directly compared endometrial cancer survivors who received brachytherapy after surgery with those who had surgery only found no significant differences in physical, emotional, or social functioning, and no significant differences in sexual function.19PubMed. Quality of life and sexual functioning in endometrial cancer survivors A separate analysis that controlled for age and type of surgery reached the same conclusion: brachytherapy was not associated with poorer health status or sexual symptoms.20PubMed. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer
That said, individual experiences vary, and the stenosis data discussed above suggest that physical changes to the vagina are real even if they do not always register on standardized quality-of-life questionnaires. Some patients do report discomfort during intercourse or worry about vaginal changes. The key practical advice is to discuss these concerns openly with your radiation oncologist before treatment starts, so you have a plan for dilator use and follow-up care.
How Imaging Has Improved Brachytherapy
One of the biggest advances in brachytherapy over the past two decades has been the shift from two-dimensional planning, where doses were calculated based on standard reference points on an X-ray, to three-dimensional image-guided planning using CT or MRI. This allows clinicians to see the actual shape of the tumor and the surrounding organs in each individual patient, rather than relying on one-size-fits-all assumptions. The result is better coverage of the cancer and lower doses to the bladder, rectum, and small bowel.21Europe PMC. Brachytherapy in the treatment of cervical cancer: a review Modern protocols, such as those developed by the international EMBRACE consortium, use MRI-based adaptive planning to tailor each brachytherapy session to the patient’s anatomy on that specific day.22Pathology and Oncology Research. MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience
Molecular Profiling and the Future of Who Gets Treated
Perhaps the most exciting development affecting brachytherapy for uterine cancer is not about the radiation itself but about figuring out which patients actually need it. Endometrial cancers can now be classified into molecular subtypes, and those subtypes predict how much benefit a patient gets from radiation. Analysis of the PORTEC-1 and PORTEC-2 trial populations found that patients with a specific mutation (called POLE-mutant tumors) had excellent outcomes regardless of whether they received radiation, suggesting they could safely skip it entirely. Patients with a different subtype (called NSMP, for “no specific molecular profile”) benefited clearly from vaginal brachytherapy, making it the treatment of choice for that group. And patients with the most aggressive molecular subtype (p53-abnormal) appeared to benefit from full pelvic external beam radiation more than from brachytherapy alone.23PubMed Central. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
The PORTEC-4a trial put this molecular-guided approach to a prospective test. Patients with high-intermediate risk endometrial cancer were assigned adjuvant treatment based on their tumor’s molecular profile rather than traditional clinical and pathological factors alone. The result: 46% of patients with a favorable molecular profile were safely spared any adjuvant treatment at all, reducing overtreatment without sacrificing cancer control.24The Lancet Oncology. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer This matters because it means fewer patients undergoing brachytherapy sessions they do not need, while the patients who do benefit get more appropriately targeted therapy. As molecular testing becomes routine in pathology labs, the population of patients referred for vaginal cuff brachytherapy will likely shrink but become more precisely selected.
Managing Anxiety During Treatment
Even though vaginal cuff brachytherapy sessions are short, the experience of having an applicator placed internally while lying still on a treatment table can be stressful. Pain during the procedure is usually mild and manageable with over-the-counter pain relievers or mild sedation, but anxiety is common, especially before the first session when everything is unfamiliar. A randomized trial found that music relaxation videos used during intracavitary brachytherapy sessions significantly reduced perceived pain and anxiety levels compared with standard care alone.25SAGE Journals / Journal of Research in Nursing. Effects of music relaxation video on pain and anxiety for women with gynaecological cancer receiving intracavitary brachytherapy: a randomised controlled trial If your treatment center does not offer distraction techniques, bringing your own headphones and a calming playlist is a low-tech option worth trying.
For inoperable patients who need intrauterine brachytherapy, the procedure is more involved and typically requires conscious sedation or anesthesia, since applicators must be placed through the cervix. These patients usually have their treatments in a hospital setting rather than an outpatient clinic, and the overall treatment course, often combined with several weeks of external beam radiation, represents a significantly larger commitment of time and energy.
Radiation Safety and Bystander Exposure
A common worry for patients is whether they will be “radioactive” after treatment and pose a risk to family members. With HDR brachytherapy, the radiation source is inserted only briefly and then withdrawn and stored in a shielded unit. You are not radioactive when you leave the treatment room. There is no need to avoid close contact with children or partners after an HDR session. The safety infrastructure behind each treatment is extensive, with international guidelines covering facility design, equipment maintenance, quality assurance, and emergency preparedness to prevent accidental radiation exposure to patients and staff alike.26PubMed Central. Multi-Organizational Insights Into Radiological Safety Standards in High-Dose Rate Brachytherapy The older LDR approach, which did involve a source remaining in place for extended periods, required some radiation precautions during the hospital stay, but this method is now rarely used for uterine cancer.